---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000043"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:06:40.820196+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics outlines 2025 priorities; Phase 3 MG trial to start in 1H25

## Summary
- Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track for 1H25; primary endpoint is MG-ADL improvement ≥3 points at Month 4 vs placebo.
- Update Phase 2b MG data: average MG-ADL reduction of 5.5 at Month 4 (n=12); deepening responses over time; no need for preconditioning chemo.
- Phase 2 SLE trial of Descartes-08 enrolling; data readout expected in 2H25. SLE affects ~1.5M people in the US.
- Descartes-15 Phase 1 dose escalation ongoing in multiple myeloma; after Phase 1, will assess in autoimmune indications.
- Cash runway expected to support operations, including completion of Phase 3 MG trial, into mid-2027.

## SEC filing metadata
- accession: 0001453687-25-000043
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000043/0001453687-25-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000043/rnac-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000043
- JSON: https://secwatch.observer/filing/0001453687-25-000043.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.